Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
{{output}}
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, there... ...
